Advertisement

An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy

  • Majid AssadiEmail author
  • Reza Nemati
  • Hossein Shooli
  • Seyed Javad Rekabpour
  • Iraj Nabipour
  • Esmail Jafari
  • Ali Gholamrezanezhad
  • Abdullatif Amini
  • Hojjat Ahmadzadehfar
Image of the Month
  • 41 Downloads
Part of the following topical collections:
  1. Image of the month

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Patient consent

The patient was informed and signed a consent form.

References

  1. 1.
    Komor J, Reubi JC, Christ ER. Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary. 2014;17:227–31.CrossRefGoogle Scholar
  2. 2.
    Maclean J, Aldridge M, Bomanji J, Short S, Fersht N. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary. 2014;17:530–8.CrossRefGoogle Scholar
  3. 3.
    Baldari S, Ferrau F, Alafaci C, Herberg A, Granata F, Militano V, et al. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary. 2012;15(Suppl 1):S57–60.CrossRefGoogle Scholar
  4. 4.
    Dworakowska D., Grossman A. B. Aggressive and malignant pituitary tumours: state-of-the-art, Endocr Relat Cancer 2018.Google Scholar
  5. 5.
    Biousse V, Newman NJ, Oyesiku NM. Precipitating factors in pituitary apoplexy. J Neurol Neurosurg Psychiatry. 2001;71:542–5.CrossRefGoogle Scholar
  6. 6.
    Ghasemi M, Nabipour I, Omrani A, Alipour Z, Assadi M. Precision medicine and molecular imaging: new targeted approaches toward cancer therapeutic and diagnosis. Am J Nucl Med Mol Imaging. 2016;6:310–27.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Basu S, Alavi A. PET-based personalized management in clinical oncology: an unavoidable path for the foreseeable future. PET Clin. 2016;11:203–7.CrossRefGoogle Scholar
  8. 8.
    Choudhury P, Gupta M. Personalized & precision medicine in cancer: a theranostic approach. Curr Radiopharm. 2017;10:166–70.CrossRefGoogle Scholar
  9. 9.
    Teunissen JJ, Krenning EP, de Jong FH, de Rijke YB, Feelders RA, van Aken MO, et al. Effects of therapy with [177Lu-DOTA 0,Tyr 3]octreotate on endocrine function. Eur J Nucl Med Mol Imaging. 2009;36:1758–66.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Majid Assadi
    • 1
    Email author
  • Reza Nemati
    • 2
  • Hossein Shooli
    • 1
  • Seyed Javad Rekabpour
    • 3
  • Iraj Nabipour
    • 4
  • Esmail Jafari
    • 1
  • Ali Gholamrezanezhad
    • 5
  • Abdullatif Amini
    • 6
  • Hojjat Ahmadzadehfar
    • 7
  1. 1.The Persian Gulf Nuclear Medicine Research Center , Department of Molecular Imaging and Radionuclide Therapy (MIRT), Bushehr Medical University Hospital, Faculty of MedicineBushehr University of Medical SciencesBushehrIran
  2. 2.Department of Neurology, Bushehr Medical University Hospital, Faculty of MedicineBushehr University of Medical SciencesBushehrIran
  3. 3.Department of Oncology, Bushehr Medical University Hospital, Faculty of MedicineBushehr University of Medical SciencesBushehrIran
  4. 4.Department of Internal Medicine (Division of Endocrinology), Bushehr Medical University Hospital, Faculty of MedicineBushehr University of Medical SciencesBushehrIran
  5. 5.Department of Radiology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  6. 6.Department of Cardiology, Bushehr Heart Medical Center, Faculty of MedicineBushehr University of Medical SciencesBushehrIran
  7. 7.Department of Nuclear MedicineUniversity Hospital BonnBonnGermany

Personalised recommendations